Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
about
Synthetic Peptides as Protein MimicsHIV-1 entry inhibitors: recent development and clinical useHIV-1 envelope glycoprotein structureRational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.The M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideDiscovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32MAsymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingSusceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsMolecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanismEfficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1Closing the door to human immunodeficiency virus.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyTwo M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide designHydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticMultivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubilityDiscovery of entry inhibitors for HIV-1 via a new de novo protein design framework.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.Enhanced potency of bivalent small molecule gp41 inhibitors.Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potencyPeptides corresponding to the predicted heptad repeat 2 domain of the feline coronavirus spike protein are potent inhibitors of viral infectionBiochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designTargeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketEmerging paramyxoviruses: molecular mechanisms and antiviral strategiesThe improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicityScreening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A.The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
P2860
Q26770255-3AB37E2B-4EA7-4183-99FD-11673167D7E9Q27003887-20840D90-0BD9-4091-AD21-4F5D0DC42513Q27011248-0C898A62-85B9-456C-9E82-76400CB91140Q27315206-6FCDBE42-DF07-4207-BEA9-EBB443BD59A1Q27671434-F5D58899-19FD-4FA9-B7F3-B73BEE8FA832Q27676641-8D35A996-F255-406A-BFB3-20A93E80C993Q27678581-FB95A22C-9C95-4992-B8F9-06471DDB2806Q27679547-5F22C0E5-8403-417A-81E5-8EDB647484E3Q28471980-BF3EF843-0036-4633-91FC-942FFA469A68Q28477409-9F0BCBBB-F84A-4AAF-959D-46049F1DFA2BQ28544927-E2DC1CCA-BFBB-45E1-B412-4499D9957BAFQ28729936-25E8DE9B-1DCC-4DD9-8E17-C89E31B5D9DBQ30428089-8A3C63AB-0019-46D3-BCF6-5C6918DE37EEQ30661709-BAAC97EE-2E4E-481F-AC05-8D90E268453FQ33713101-90459C1F-F0B0-45B4-9208-AAC58D5B1352Q33951142-A38229C2-72A0-4431-A62E-821D627C4C81Q34059855-8649DE1E-736F-45FA-B83A-17E1825D0F1FQ34069846-0D323FFA-C044-44AE-9C45-FB507FC2292CQ34149681-44090444-2285-48E8-A985-8F06B850E988Q34150117-712C89AA-6D55-4605-8428-18FE964BF8D8Q34189558-59092D95-6DC0-4BD0-AE30-9E3030C401D6Q34298481-E00D8117-960D-476C-B843-2569E08C53ACQ34385987-5B34AE35-E6A4-4873-BCF6-C41AAA429FDCQ34517381-8B240E10-5DBE-4775-B8A5-233656450A03Q34536817-37E6AFC0-EB6F-4B02-89E8-09E0FD8AB33DQ34546445-8D9BC874-10F5-4AAD-9B6A-EF866E1F9C33Q34664366-703D940C-7F38-4C29-9181-41BA51BF82EDQ34682512-1CF17CD0-8A95-4E33-9FA7-B3D2D9C1EBCFQ34800822-B2FCBEA2-ECD4-4C49-A61D-CD6BD3FB0F89Q35061450-19EF18AE-D0FD-4C0C-BFDD-60A1E94002C0Q35563298-7B51CB83-C3A3-43FC-A704-8DDBD0A75FB5Q35615810-29F5E0B8-0929-491B-BA11-D1830038BA4CQ35641194-A01D3C9F-D523-489D-A338-D7B7497C4115Q35658152-8CB89E49-CD85-4982-AA00-EF5DC1639C73Q36282554-7443C5C2-DA7F-4980-A601-152002FEC842Q36334376-34FFEDC4-A71C-475D-BBF3-93B1B2437D49Q36558535-1DB2C041-99C3-4CBC-93DC-887C7AF426DFQ36559811-3E6C885F-30F7-4DE9-9D7E-3EB2EF638255Q36634815-18390706-8EA2-4AF0-BBD8-5FCEF1C15B45Q36945152-F925D200-53FA-47A0-909F-807713D9A975
P2860
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@en
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@nl
type
label
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@en
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@nl
prefLabel
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@en
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@nl
P2093
P356
P1476
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
@en
P2093
Haifeng Song
Linqi Zhang
Qing Liang
Weiguo Jing
Yonghong Xiao
P304
11126-11134
P356
10.1074/JBC.M800200200
P407
P50
P577
2008-02-26T00:00:00Z